BOSTON – At the presidential plenary session of the 2017 annual meeting of the American Academy of Neurology, Ronald Petersen freely admitted that "I'm biased."
Methods to manipulate gene expression in Bacteroides, the most common type of bacterium in the gut microbiome of Western populations, have been developed and reported by two separate research groups.
The approval of Roche Holding AG's Ocrevus (ocrelizumab) last month made it the first FDA-approved multiple sclerosis (MS) drug that provided benefit to patients with primary progressive MS. (See BioWorld Today, March 30, 2017.)
A dendritic cell vaccine against a viral antigen induced long-term survival in three out of 11 treated glioblastoma patients, scientists reported in the April 15, 2017, issue of Clinical Cancer Research.
Age-related changes to the microbiome contributed to intestinal dysbiosis and inflammation, and the microbiome changes were reversible by reducing levels of tumor necrosis factor (TNF).
Exome sequencing of more than 10,000 individuals from an area of Pakistan with a high rate of cousin marriage has enabled researchers to identify more than 1,300 genes that were functionally absent in at least one person.
Reducing expression of the protein ataxin-2 improved symptoms in mouse models of both spinocerebellar ataxia type 2 (SCA-2) and amyotrophic lateral sclerosis (ALS), scientists reported this week. Their findings appeared in two back-to-back papers in the April 13, 2017 issue of Nature.
A monoclonal antibody isolated from a survivor of Marburg virus infection protected primates from death due to infection with either Marburg virus or the related Ravn virus, even if it was given five days after infection.
WASHINGTON – “Hallmarks and enabling characteristics should be not special cases, but rather reasonably broad across the spectrum of human cancers,” Robert Weinberg told BioWorld Today.
WASHINGTON – Researchers at Yale University have received conditional approval for a clinical trial that will test whether isocitrate dehydrogenase (IDH)-mutated tumors might respond better to poly-ADP ribose polymerase (PARP) inhibitors than to IDH inhibitors.
